Omid Farokhzad, M.D.
Associate Professor
Brigham and Women's Hospital
Harvard Medical School
       Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center. He is additionally a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. Dr. Farokhzad's research is focused on the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 130 papers (>23,000 citations; H-Index 61) and holds more than 140 issued/pending US and International patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS and MIT formed the basis for the launch of four biotechnology companies: BIND Therapeutics (NASDAQ: BIND), Selecta Biosciences, Tarveda Therapeutics (formerly Blend Therapeutics), and Koan Biotherapeutics, which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr. Farokhzad has served in various capacities on the Board of Directors and the Scientific Advisory Board of these companies. He was a recipient of the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes, for the development and industrialization of nanoparticle technologies for medical applications. In 2014, he received the Golden Door Award from the International Institute of New England for his societal and economic impact as a naturalized USA citizen. In 2015, he was named as one of The Worldview 100 by Scientific American, which recognized visionaries who shape biotechnology around the world. In 2016, he was among the recipients of the Ellis Island Medal of Honor for his scientific, societal and economic contributions to America as an immigrant. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was selected by Thomson Reuters among the Highly Cited Researchers in 2014 and 2015. The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. Dr. Farokhzad completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine and his M.B.A. from the MIT Sloan School of Management

Read more about Dr. Farokhzad

  • Dr. Farokhzad was elected as a member of the College of the Fellows of the American Institute of Medical and Biological Engineering (AIMBE) and has been recognized "for pioneering nanotechnology research in the field of cancer therapy, all the way from conception to human clinical testing." ( Read more...)
  • Dr. Farokhzad was honored as one of fifteen recipients across all industries of “All Star Distinguished Achievement Award”, from the Mass High Tech. (Read more...)
  • Dr. Farokhzad was highlighted by Forbes, Forbes has highlighted the important role of nanotechnology in driving forward the pharmaceutical industry with three of their top five nanotech breakthroughs in 2006 having biological applications. (Read more...)
  • Dr. Farokhzad was highlighted by Scientific American in article "Nanoparticles Annihilate Prostate Cancer", talking about how nanotechnology is playing a critial role in fighting cancer. (Read more...)
  • Dr. Farokhzad was highlighted by article "Magic Nano-Bullets", which tells the story of the how the advances in nanotechnology could make drug delivery far more accurate and effective. (Read more...)